# Merck's phase 3 keynote-564 trial met key secondary endpoint
**FDA Update**

**2023-11-01 10:41**

**https://www.ainvest.com/news/merck-s-phase-3-keynote-564-trial-met-key-secondary-endpoint-23111000108ce72c5bd2b9b5/**

Merck's phase 3 keynote-564 trial met key secondary endpoint